Effect of sulfinpyrazone on ventricular fibrillation during acute myocardial ischemia.
In patients treated with sulfinpyrazone, an apparent reduction in the incidence of sudden death and presumed ventricular fibrillation has been reported. Using an intact animal model without microcirculatory thrombosis, we studied the effects of sulfinpyrazone on ischemic myocardium in 58 anesthetized dogs divided into three groups: control untreated (n =24), group 1 (n = 16), treated daily with 300 mg of sulfinpyrazone for 7 days, and group 2 (n = 18), treated daily with 300 mg of sulfinpyrazone for 7 days but omitting treatment on day 8. Although consistent hemodynamic differences were not apparent, the degree of injury determined by ECG mapping was significantly lower in group 1. The incidence of fibrillation was 54% for control and 0% in group 1. Group 2 had a 44% incidence, suggesting a limited duration of action. The apparent absence of microcirculatory thrombosis in this model suggests other mechanisms of action. A significantly smaller increase in tissue water and Na+ and smaller loss of K+ in group 1 may have contributed to the lower incidence of fibrillation, perhaps through selective prostaglandin inhibition.
D000208:Acute Disease; D000818:Animals; D001157:Arterial Occlusive Diseases / Q000150:complications; D001794:Blood Pressure; D003327:Coronary Disease / Q000150:complications*; D004285:Dogs; D004562:Electrocardiography; D004573:Electrolytes; D005230:Fatty Acids, Nonesterified / Q000097:blood; D008297:Male; D013318:Stroke Volume; D013442:Sulfinpyrazone / Q000627:therapeutic use*; D014693:Ventricular Fibrillation / Q000150:complications / Q000188:drug therapy* / Q000401:mortality
D004573:Electrolytes; D005230:Fatty Acids, Nonesterified; D013442:Sulfinpyrazone